Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sarissa is doing what it has to to get this going. It is as simple as that. You either believe this is true and buy more, or if you do not by all means sell.
They are drilling cores, getting assays and are about to come out with their first NI 43-101 report.
They have raw materials that are in extremely high demand world-wide and that is what makes this so exciting for us.
Everything else (JV, more Financial reporting, eventual uplisting) will come in it's time. I happen to believe all this will happen this year, but that is JMO.
In My Opinion The difference between people who post negative info (and I will quote you "It has lost it sparkle and will not get it back till compliance but in the mean time the price will drop even more...") and the longs who have been on SRSR for a year or more are the bashers will post whatever they have to to bring the PPS down so they can buy as cheap as possible & flip again making profit each time. Most of us are not 'professional' day-traders, but have real jobs and trade as a supplement or in the hopes that we eventually can retire off our profits. For me, I cannot post negative junk just to bring down a stock's price so I can profit from it. It hurts others and I believe it is wrong... I try to think about everyone else who is in the stock besides me. I guess many out here do not care about anyone but themselves...
Most of the longs here are true believers in Sarissa just keep our shares and add from time to time without bashing it to make the PPS drop to get new shares cheaper.
That is my fundamental issue with so-called negative DD.
If you are currently Not in this stock, why post at all? If you decide to get back in, by all means if you come up with good DD that may help the pps rise, post away. I see no point at all in posting negative anything unless there is some extraordinary reason to do so. If you own SRSR, you should want the pps to go up, not down.
All IMHO.
Cheers All,
TheGoodlifeGeo
But, IMO, the point is that they should know this already or not take it upon themselves to delete posts in the first place.
Each of these boards has a set of Mods who actually know the stock, sector, industry and what is/is not pertinent to that particular stock. Why in the World are the Admins getting involved with deleting individual posts at all?
They should be overseeing the general day-to-day operations of IHUB and not getting involved in individual posts Except when posts are removed by a Mod and a person wants a higher review.
The Mods should be the Only ones removing posts from boards and Admins should be over the Mods in case of issues between subscribers and Mods...
This is one the biggest reasons I do not post more on Ihub. I get so turned off by the very selective & arbitrary deletions that it is too often just not worth it.
When Goforthebet, who is one of our Best Posters, has extremely helpful DD posts deleted like this and Stops posting on a board because of it, this Hurts Ihub and the Stock that the board is supposed to be representing.
Meanwhile posters like MTP are allowed to post Crap and personally slanted lies and are protected by words of "Free Speech". I recently got into this argument with a Mod on another board who constantly protects Bashers and deletes posts with real DD. I am gone from that board and sold my stock there... I know at least 3 others who did the same thing this week.
I am with Homey, I am going to let my paid membership go at the end of this round and stop.
OK, off my soapbox for today... lol...
Cheers and GTLA,
TheGoodlifeGeo
Converge has only just begun on this venture, like one day, so they could not possibly have any news yet.
Come back in a month and maybe Converge will have an update on the Sarissa JV property...
SRSR has Most Certainly proven what they have in the ground with Drilling & Assay Reports, which you should know. They are putting this all together in an NI 43-101 report that will be finished soon.
They also have kept us apprised with PR's on a regular basis. No reasonable person could or should expect more than we have received.
Cheers All,
TheGoodlifeGeo
I made a post about Greg being a Crime fighting Super-Hero a while back. Maybe I was right?
I am buying more before the open tomorrow... Probably not alone in this...
And I Love Cornbread...
Tomorrow will be better than today and I think this has the earmarks of a 3+ day run...
Then the symbol change comes in and we go again...
Then Greg starts announcing more plans and we go again...
All the naysayers can say whatever they want. This company is going to Rock!
Greg wants to show the world what he is really all about and become rich and famous doing it... He will make us rich doing it as well...
All IMHO.
Cheers All,
TheGoodlifeGeo
At this moment, it is 50 degrees and sunny. Tomorrow they are saying at my house I will have 10-16" of Snow and a high temp of 20...
Welcome to Spring!
Cheers All,
TheGoodlifeGeo
Tivo (TIVO) & Blockbuster (BBI) announced JV news today.
Blockbuster will Sell Tivo DVR's at all their locations and push Tivo online.
Tivo will include & advertise Blockbuster On-Demand on all new models.
http://www.b2i.us/profiles/investor/ResLib...29160&Category=1195
Picked up some TIVO today and have a pre-buy in for tomorrow...
Might be worth watching...
Cheers All,
TheGoodlifeGeo
And it's about time too... (not that I was worried or anything... It was just a matter of time for this to start Up again...)
Cheers All,
TheGoodlifeGeo
Hey Zig,
I bought shares today and just placed a pre-market buy for more...
I think you could be right about breaking $8.00
I am going to spread the word as well. Let see what we can do with this...
Cheers,
TheGoodlifeGeo
Blockbuster & Tivo Agreement News out:
http://www.b2i.us/profiles/investor/ResLibraryView.asp?BzID=553&ResLibraryID=29160&Category=1195
Blockbuster And TiVo Announce Agreement To Make BLOCKBUSTER® OnDemand Available Through The TiVo Service And to Promote TiVo DVRs Throughout Retail Stores Nationwide
Blockbuster to Make Extensive Library of Digital Content Available to Millions of TiVo Movie Enthusiasts
Further Distinguishes TiVo as the Best Single Solution for Delivery and Easy Navigation of Broadband Content to the TV
ALVISO, CA, and DALLAS, TX (March 25, 2009) – Blockbuster Inc. (NYSE: BBI, BBI.B), a global leader in entertainment, and TiVo Inc. (NASDAQ: TIVO), the creator of and a leader in television services for digital video recorders (DVRs), today announced they are joining forces to deliver Blockbuster's vast library of premium digital movie titles directly to the television set via TiVo® DVRs.
BLOCKBUSTER OnDemand, featuring content to both buy and rent, will be integrated into TiVo Series2™, Series3™, TiVo HD, and TiVo HD XL DVRs. The move by two leaders in home entertainment will make it even easier for all broadband connected TiVo subscribers to download Blockbuster's content and enjoy a complete television entertainment experience on their individual schedules using TiVo, the best and most comprehensive single solution for delivery and simple, intuitive navigation of broadband, broadcast, and cable content – all from one remote control.
TiVo DVRs will be sold at thousands of Blockbuster® stores nationwide as well as online at blockbuster.com, giving both companies new distribution outlets and putting TiVo DVRs and BLOCKBUSTER OnDemand front and center of where video shopping takes place. Additionally, the companies will implement a cross-marketing campaign.
"We are excited to be teaming with TiVo, the company that created the DVR, to make Blockbuster's entertainment content readily available to their millions of subscribers," said Jim Keyes, Blockbuster Chairman and CEO. "Ultimately, our vision is to work with TiVo so that their subscribers can access movies not only through our OnDemand service but also from our stores and through our by-mail service as well. Regardless of a film's availability – through VOD or on DVD – we want to work with TiVo to provide their subscribers unprecedented access to movie content."
"Joining with Blockbuster further distinguishes TiVo as a true universal solution for content providers, making it a one stop shop for any content thru broadband or linear distribution straight to the TV," said Tom Rogers, President and CEO of TiVo Inc. "When consumers walk into one of the thousands of Blockbuster stores entertainment for the home is on their minds - - it could not be more natural to have them exposed to the world of millions of entertainment possibilities for the home that the TiVo Service provides."
The companies expect to have the BLOCKBUSTER OnDemand service integrated into TiVo DVRs in the second half of 2009.
BLOCKBUSTER OnDemand offers one of the most extensive libraries of digital entertainment product in the marketplace, with thousands of titles from the hottest new movie releases to the classics. For more information on BLOCKBUSTER OnDemand delivered via the TiVo service visit www.tivo.com/blockbuster.
###
About Blockbuster
Blockbuster Inc. (NYSE: BBI - News, BBI.B - News) is a leading global provider of in-home movie and game entertainment, with more than 7,400 stores throughout the Americas, Europe, Asia and Australia. The company may be accessed worldwide at www.blockbuster.com.
About TiVo Inc.
Founded in 1997, TiVo (Nasdaq: TIVO - News) pioneered a brand new category of products with the development of the first commercially available digital video recorder (DVR). Sold through leading consumer electronic retailers and our website, TiVo has developed a brand which resonates boldly with consumers as providing a superior television experience. Through agreements with leading satellite and cable providers, TiVo also integrates its DVR service features into the set-top boxes of mass distributors. TiVo's DVR functionality and ease of use, with such features as Season Pass(TM) recordings and WishList® searches and TiVo KidZone, have elevated its popularity among consumers and have created a whole new way for viewers to watch television. With a continued investment in its patented technologies, TiVo is revolutionizing the way consumers watch and access home entertainment. Rapidly becoming the focal point of the digital living room, TiVo's DVR is at the center of experiencing new forms of content on the TV, such as broadband delivered video, music and photos. With innovative features, such as TiVoToGo(TM) transfers and online scheduling, TiVo is expanding the notion of consumers experiencing "TiVo, TV your way. ®" The TiVo® service is also at the forefront of providing innovative marketing solutions for the television industry, including a unique platform for advertisers and audience research measurement.
TiVo, 'TiVo, TV your way.', Season Pass, WishList, TiVoToGo, Stop||Watch, Power||Watch, and the TiVo Logo are trademarks or registered trademarks of TiVo Inc. or its subsidiaries worldwide. © 2009 TiVo Inc. All rights reserved. All other trademarks are the property of their respective owners.
Blockbuster, the Blockbuster logo, blockbuster.com and Blockbuster Online are trademarks or registered trademarks owned by Blockbuster Inc. in the United States and/or other countries.
All other company or product names are trademarks of their respective owners and, in some cases, are used under license. Specifications, pricing and delivery schedules are subject to change without notice.
Tivo could run tomorrow...
http://www.b2i.us/profiles/investor/ResLibraryView.asp?BzID=553&ResLibraryID=29160&Category=1195
Blockbuster And TiVo Announce Agreement To Make BLOCKBUSTER® OnDemand Available Through The TiVo Service And to Promote TiVo DVRs Throughout Retail Stores Nationwide
Blockbuster to Make Extensive Library of Digital Content Available to Millions of TiVo Movie Enthusiasts
Further Distinguishes TiVo as the Best Single Solution for Delivery and Easy Navigation of Broadband Content to the TV
ALVISO, CA, and DALLAS, TX (March 25, 2009) – Blockbuster Inc. (NYSE: BBI, BBI.B), a global leader in entertainment, and TiVo Inc. (NASDAQ: TIVO), the creator of and a leader in television services for digital video recorders (DVRs), today announced they are joining forces to deliver Blockbuster's vast library of premium digital movie titles directly to the television set via TiVo® DVRs.
BLOCKBUSTER OnDemand, featuring content to both buy and rent, will be integrated into TiVo Series2™, Series3™, TiVo HD, and TiVo HD XL DVRs. The move by two leaders in home entertainment will make it even easier for all broadband connected TiVo subscribers to download Blockbuster's content and enjoy a complete television entertainment experience on their individual schedules using TiVo, the best and most comprehensive single solution for delivery and simple, intuitive navigation of broadband, broadcast, and cable content – all from one remote control.
TiVo DVRs will be sold at thousands of Blockbuster® stores nationwide as well as online at blockbuster.com, giving both companies new distribution outlets and putting TiVo DVRs and BLOCKBUSTER OnDemand front and center of where video shopping takes place. Additionally, the companies will implement a cross-marketing campaign.
"We are excited to be teaming with TiVo, the company that created the DVR, to make Blockbuster's entertainment content readily available to their millions of subscribers," said Jim Keyes, Blockbuster Chairman and CEO. "Ultimately, our vision is to work with TiVo so that their subscribers can access movies not only through our OnDemand service but also from our stores and through our by-mail service as well. Regardless of a film's availability – through VOD or on DVD – we want to work with TiVo to provide their subscribers unprecedented access to movie content."
"Joining with Blockbuster further distinguishes TiVo as a true universal solution for content providers, making it a one stop shop for any content thru broadband or linear distribution straight to the TV," said Tom Rogers, President and CEO of TiVo Inc. "When consumers walk into one of the thousands of Blockbuster stores entertainment for the home is on their minds - - it could not be more natural to have them exposed to the world of millions of entertainment possibilities for the home that the TiVo Service provides."
The companies expect to have the BLOCKBUSTER OnDemand service integrated into TiVo DVRs in the second half of 2009.
BLOCKBUSTER OnDemand offers one of the most extensive libraries of digital entertainment product in the marketplace, with thousands of titles from the hottest new movie releases to the classics. For more information on BLOCKBUSTER OnDemand delivered via the TiVo service visit www.tivo.com/blockbuster.
###
About Blockbuster
Blockbuster Inc. (NYSE: BBI - News, BBI.B - News) is a leading global provider of in-home movie and game entertainment, with more than 7,400 stores throughout the Americas, Europe, Asia and Australia. The company may be accessed worldwide at www.blockbuster.com.
About TiVo Inc.
Founded in 1997, TiVo (Nasdaq: TIVO - News) pioneered a brand new category of products with the development of the first commercially available digital video recorder (DVR). Sold through leading consumer electronic retailers and our website, TiVo has developed a brand which resonates boldly with consumers as providing a superior television experience. Through agreements with leading satellite and cable providers, TiVo also integrates its DVR service features into the set-top boxes of mass distributors. TiVo's DVR functionality and ease of use, with such features as Season Pass(TM) recordings and WishList® searches and TiVo KidZone, have elevated its popularity among consumers and have created a whole new way for viewers to watch television. With a continued investment in its patented technologies, TiVo is revolutionizing the way consumers watch and access home entertainment. Rapidly becoming the focal point of the digital living room, TiVo's DVR is at the center of experiencing new forms of content on the TV, such as broadband delivered video, music and photos. With innovative features, such as TiVoToGo(TM) transfers and online scheduling, TiVo is expanding the notion of consumers experiencing "TiVo, TV your way. ®" The TiVo® service is also at the forefront of providing innovative marketing solutions for the television industry, including a unique platform for advertisers and audience research measurement.
TiVo, 'TiVo, TV your way.', Season Pass, WishList, TiVoToGo, Stop||Watch, Power||Watch, and the TiVo Logo are trademarks or registered trademarks of TiVo Inc. or its subsidiaries worldwide. © 2009 TiVo Inc. All rights reserved. All other trademarks are the property of their respective owners.
Blockbuster, the Blockbuster logo, blockbuster.com and Blockbuster Online are trademarks or registered trademarks owned by Blockbuster Inc. in the United States and/or other countries.
All other company or product names are trademarks of their respective owners and, in some cases, are used under license. Specifications, pricing and delivery schedules are subject to change without notice.
I'll Take IT!!! Lets see .49 on the Assay report and double that on JV, then double again on production news... I'll be emailing from a beach in Brazil if this happens...
I am having trouble reading that NI report... On the section entitled "Results of the final model", is this just one section of the mine or the total expected return?? Not very much if this is a total... $361 Million @ 900/ounce?
We will have many $Billion$ not just Millions.
Hopefully our report is better than this one...
Cheers All,
TheGoodlifeGeo
WOW!!! Not look for a few days and See what Happens!!!
I knew Greg would start getting this going again. This is just going to keep getting better IMHO.
Cheers everyone,
TheGoodlifeGEo
OK, what is it with you and "years" today? I sense a recurring theme... lol... Not everything will take "years" now that we are so close to the NI report.
The Impact for Sarissa will be felt right now and for at least the next 3 years with the infusion of capitol.
They will also get their money regardless of whatever Converge does or does not do.
I also like what I see from Converge so far. Just starting to do some DD on them and I like it so far.
Look at it this way, if they do what they are intending to do, in a few years Sarissa will have revenues coming in from this Gold operation as well as Nemegosenda's Niobium/Tantalum operations...
Who knows what other properties they will be exploring by then?
Cheers All,
TheGOodlifeGeo
OK, maybe it will take years for the JV company to start mining, but who cares? This stock will almost certainly go to a new all time high as soon as it is announced. I am hoping for at Least several times the all time high personally...
Once actual Mining starts, that is when this will go to $Dollars...
I also do not believe they will use someone too small for the Nemegosenda property, but that is for Scott & company to decide... I have total confidence that Scott will go with the best company for the work in both Value ($$) for us and be able to perform.
All IMHO.
Cheers All,
TheGoodlifeGeo
I do not agree with years here... No way does Scott wait years for a JV. He wants this to get going even more than we do. I would be surprised if he is not in pre-talks already.
The mining world is actually quite small and I am certain that everyone in this type of mining in North America knows about Sarissa. They do their own DD to keep on top of this too.
The only thing stopping Sarrisa from pursuing a JV is the NI Report and we know that this will be done soon.
All IMHO.
Cheers All,
TheGoodlifeGeo
Are you joking or just not paying attention?
"There very well maybe more buying but it is not enough to overcome the sellers"
We had over 440,000 in buys this morning and all it took to bring it down to .018 was one 10K share sell and another of 5K to bring it down to .0175 Then for absolutely no reason at all the ask is dropped to .017
Sure, there is no manipulation here at all...
Maybe we do not have enough sustained buying, but after all the buying this morning, some MM or a few not so bright investors (I'd bet the first one...) brought the PPS down 10% on $270 worth of stock...
They know they can do this right now so they do. It is still manipulation...
All IMHO.
Cheers All,
TheGoodlifeGeo
We have a really strange trend going here...
Every time we get Really Great News (and this PR was Really Great News!) someone sells a very small number of shares below the ask and brings the stock down.
We have over 300K in buys and only 35K sells and yet the pps is down today... There is NO good explanation for this except blatant manipulation. Any stock with a nearly 10 to 1 ratio of Buys/Sells should be Up!
Anyway, just venting...
This is a fantastic deal for Sarissa!
This gives them active capitol to use for exploring, drilling, assaying and also gives them a source of income for the future.
A Win/Win for Scott & Company...
Cheers All,
TheGoodlifeGeo
Sometimes TDA pulls this too but on this stock, The last time I bought it, TDA said "The Ask is significantly higher than the Bid for this security, please check to see that you are on the right stock..." yada, yada, yada...
I called TDA and said "That's because it's going to Open 20% higher than it is right now..." lol...
When it does this, I get around this by using Buy Stop market instead of just a Limit order and it always goes though.
Isn't this a nice day today! We should get at least a few days out of this run, then we are at a much higher new bottom for the next news and another run...
Little dip here... Time to buy again...
Cheers all on a nice Green day,
TheGoodlifeGeo
You know I really do feel bad for you. I have done this with my share of stocks as well (currently holding asfx from last year... enough said...) so I hope this does go to $1 and you can almost double your money... and I will have a nice addition to my retirement fund...
2003 was Tough on Stem... Not just here either. New ballgame now. For at least the next 4-8 years, Stem is in the right place at the right time...
Hopefully we not only un-do what happened from 2001 - 2008, but the reversal is so huge and the advancements are so Big that if the regime changes again in 4 or 8 years, they cannot go back...
I have been emailing my friend who works in a Stem program down in Tx and he is So excited he can barely contain himself. He has started putting out feelers for other openings and he says they are popping up all over the country.
Companies that did what they had to control costs and stay alive during the "Dark Ages of Stem" will come back and thrive now...
All IMHO.
Cheers All,
TheGoodlifeGeo
Freakin' Awsome!!! I am glad I do not need to buy this report though... 5K is a bit much for me... LOL...
Totally Fantastic Close Today! Good job to whomever did this buying. We (all us who are out of dry $$$ at the moment) thank you Very Much!
I wish I could see what is in the report... I wonder if it is legal for someone who gets the report to post just the Sarissa part without copyright violations?? Probably not...
Well, this was a nice surprise for a change. Logging in and seeing Green! Green is SO much nicer than Red... I was 4 for 5 Green today in my TDA account today so maybe things really are turning around! Hope So...
Thanks Rig & Go for the great Posting...
Cheers Everybody!
TheGoodlifeGeo
OK, just catching up on posts. Others have said this, but this one does not need pumping. This company and any other viable Stem Cell company for that matter.
MCET has many patents, current product, active partnerships with other companies who all also have current product, some of them very big companies.
They are actively making & pursuing new partnerships with other companies and working in a cooperative effort with the basic goal to help people who are sick.
Sure, they will make some money along the way as well, hopefully a Lot of $$$!!! This is Big Business now, but have you ever actually Talked to someone in this kind of research?
They are a special breed of human... Most of these people work insane hours for typically not so great pay. Some research scientists and doctors in this field do well if the company get patents on their methods or own a piece of the company, but the ones I have talked to recently never talk about the money, only the work. They get So Excited whenever they are talking about the potential of what they are doing. They make is sound so cool. They help save lives and they love the work they do. It's actually interesting listening (even though you will likely not understand a single word...).
I think this company is doing great and will keep doing so...
All JHMO.
Cheers All,
TheGoodlifeGeo
Nice One Go!!! (As always...)
Cheers,
TheGoodlifeGeo
Scott Keevil Cannot Dump. All his shares are Restricted until November 2009.
If you asking if the company is releasing shares, Call and Ask them.
I know what Scott & Alan are doing. They are writing the NI Report... This is pretty much all they will be doing until it is finished. OK, Scott might be in pre-talks with whomever might be interested to get ready for After the NI report is sent ready... We will all know more pretty soon.
The PPS fall today should not have happened. As syracuseo said, the the action today was Buys not Sells.
Buys 669,500 Sells 413,323
Extremely low trading right now and someone moved the bid down... The ridiculous so-called "trade" at .0155?? You could not convince me that is not manipulation.
If there was Dumping going on, it would be in the many millions of shares, not a few hundred thousand...
SRSR will not ever dump.
Scott is not in this for quick pocket change, he is in this to bring in a world-class mine.
All IMHO.
Cheers All,
TheGoodlifeGeo
MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer with Maxim Biotech
Info about the company they signed with, Maxim Biotech:
http://www.maximbio.com/
Maxim Biotech, Inc. was founded in July 1992 in the state of California. The principal office and R&D laboratory are located in South San Francisco, California. The San Francisco Bay Area is known for its biotechnology research and development, and companies located in this area dominate the biotechnology industry of the United States and worldwide. January 2006, Maxim Biotech has relocated its operation to Rockville Maryland, a 30,000 square feet space that is FDA approved cGMP manufacture facility.
Maxim Products listed in Fisher Scientific Catalog:
http://www.fishersci.com/wps/portal/SEARCHRESULTS?LBCID=40750357&searchType=Rapid&catCode=ALL&weblinkDisplayText=View%20All%20Maxim%20Quantitative%20Competitive%20PCR%20(QC-PCR)%20Kits&keyWord=MaximBiotechQCPCRKits
Cheers All,
TheGoodlifeGeo
I "Try" to as well, but it hardy ever works... LOL...
Sorry you got out... But you just never know on Any of these stocks there days... All we can do is make the best choices we can.
I bought MCET and another Stem Company just on the belief that things were starting to happen. When I saw the financials and saw how aggressively they had cut expense, I knew they would not only make it, but should Thrive.
I think Stem Cell is just going to go Nuts over the next few years... Of course, those doing well will likely get swallowed by larger companies and then we will have just a few companies controlling it all...
All IMHO...
Cheers,
TheGoodlifeGeo
You really do not know anything about this do you?
This is what they Do. They Develop Specialized products from Stem Cell technology to Combat Disease.
And this is not a "study".
"MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer"
The money potential from this Huge and will be more so in the coming years...
All IMHO.
Cheers All,
TheGoodlifeGeo
MCET - Up 54% on over 11 million in volume and News:
http://biz.yahoo.com/prnews/090319/cl86146.html?.v=1
Glad I did not sell and bought more last week...
Cheers All,
TheGoodlifeGeo
I feel for you... Been there, done that...
I've had this kind of silently for quite a while, ever since the first news story was leaked that Obama was reversing the Stem Cell stuff from the previous administration.
I figured it was just a matter of time...
The general economy was hurting everyone last year, but we are starting brand new here and companies are learning and dealing with it...
Look how well MCET managed and cut their costs. Over 1 Million was cut from expenses.
Some have said this may sit until they have something new in clinical trials. I say that although this would certainly give this stock another boost, they already Have Customers, Product and a Thriving industry they can and will tap into.
Do not get caught up in what Kind of Stem Cell research a particular company is doing. ALL Stem Cell will be hot for the next few years and more than likely beyond.
If you do your DD on a company and they have viable product, customers, and ongoing research (Like MCET Does!), they are probably going to do Extremely well.
Stem Cell & NanoTech are Hot businesses to be in now.
MCET is Red Hot right now!
It is Not too late to get in here. This has just begun...
All JMHO...
Hope some stayed in here and bought more when it was down...
Cheers All,
TheGoodlifeGeo
The only reason I have to believe this will one day either go to a real board or be bought out by a bigger player are the patents & intellectual property they own.
The past 2 years have been brutal on just about every industry. Cutbacks have been broad and everywhere. If anyone thinks this has Not affected Medical Research, they should think again. There simply has not been the kind of money available that there once was.
This is going to change and change quickly. The 'status' of Stem Cell research in this country is undergoing a fundamental change and I am not talking about years away here I am talking this year.
Regardless of any other legislation, people are moving into this field now. In fact, the hottest 2 areas right now in medical research are Stem Cell & Nanotechnology. These 2 fields are going to explode over the next few years so I do not believe that buying any stock from a real company with real inroads into either of these growing technologies can be bad. Obviously you must ensure that the company is what is says it is and has that potential, but that is just part of any DD before buying a stock...
All IMHO.
Cheers All,
TheGoodlifeGeo
The current share structure as of March 2009:
Authorized Shares: 850,000,000
Outstanding Shares: 746,327,277
Restricted Shares: 270,241,219
Cheers All,
TheGoodlifeGeo
I think that will happen once the NI report is out... I hope so anyway. That report is what ties this all together and gives them the power to go shopping for a JV partner or buy a couple of Backhoes and start digging... OK, a couple of Dumptrucks too...
But seriously, they will be in a whole different position with the NI report than they are now without it.
Mining companies are Always looking for new rich digs to get into and I really think things are going to improve much faster than some of the Doom & Gloomers have been saying.
People Want (Need) to have their Toys... Whether that is a Shiny New Pickup Truck or that 60" Flatscreen, they Want to buy, they just have been holding off until things get better, or until someone Tells them things are better...
The Stuff that Sarissa has is the stuff the World needs to fulfill that need. I think this is simple and I am willing to wait as long as it takes to get it...
All IMHO and I bought more today...
Cheers All,
TheGoodlifeGelo
I agree 100% and nice DD moscow...
The Obama thing last week was done to pronounce that Stem Cell research is a vital part of the continuing progress towards fighting disease. This is a World Wide effort that is being pushed on Many fronts...
The 'Stem Research Enchancement ACT of 2009' is yet another step towards that goal and most of the largest companies in the medical business are behind it.
I also agree this company is a perfect takover target... I am surprised it has not happened already, but I can wait...
My shares here are not going anywhere. Reset 2-6 months and look again... Of course if things improve economy wise (as some are saying it is already) who knows what may happen.
This company is upfront and Always replies to me when I ask questions. I love the business they are in and this has no where to go but up. I bought a little more today at these crazy-low levels.
All IMHO...
Cheers and GTLA,
TheGoodlifeGeo
Interesting Good things:
1. Total operating expenses for the year ended November 30, 2008 were $2,300,818, as compared to operating expenses of $3,389,894 for the year ended November 30, 2007
A reduction of about $1,000,000 in operating Expenses
2. The total of other expense, net of other income, decreased from $34,541 for the year ended November 30, 2007 to $3,953 for the year ended November 30, 2008, representing a decrease of $30,588.
3. Net loss for the year ended November 30, 2008 was $2,094,936, as compared to a net loss of $3,172,638 for the year ended November 30, 2007, representing a decrease in the net loss of $1,077,702 (34%). The primary reasons for the decrease are the reductions in operating expenses as described above
OK, this is both good and neutral, but at least they are heading in the right direction...
Not so good:
1. November 30, 2008 November 30, 2007
Cash and cash equivalents $ 6,022 $ 411,691
Current assets $ 38,876 $ 502,704
Current liabilities (1,768,689 ) (1,724,869 )
Working capital deficiency $ (1,729,813 ) $ (1,222,165 )
But, having said that, they are also saying:
"With our strategic shift in focus on therapeutic programs and technologies, however, we expect our future cash expenditures to increase significantly as we advance our therapeutic programs into clinical trials.
We intend to add scientific and support personnel gradually. We want to add specialists for our key research areas. These strategic additions will help us expand our product offerings leading us to additional revenues and profits. Of course as revenues increase, administrative personnel will be necessary to meet the added workload. Other expenses, such as sales and customer service, will increase commensurate with increased revenues. The Company's current research and development efforts focus on development of future products and redesign of existing products"
The company is planning to focus on "therapeutic programs and technologies" which will increase the need for capital, which they believe will increase revenue.
All in all I think this was a good report. Better than many, if not most, of the rest of the companies around the world for 4Q 2008...
They made great strides to reduce & control expenses while formulating the plan they will use to increase revenues in the future.
I still want someone to buy them out though. (anything over $1/share would be nice... lol...)
Cheers and GTLA,
TheGoodlifeGeo
The Entire Filing:
Form 10-K for MULTICELL TECHNOLOGIES, INC.
--------------------------------------------------------------------------------
16-Mar-2009
Annual Report
Item 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
The Management's Discussion and Analysis for the years ended November 30, 2008 and 2007 is presented below.
Overview
Following the formation of MCTI during September 2005 and the recent in-licensing of drug candidates, the Company is pursuing research and development of therapeutics. Historically, the Company has specialized in developing primary liver cell immortalization technologies to produce cell-based assay systems for use in drug discovery. The Company seeks to become an integrated biopharmaceutical company that will use its immune system modulation technologies to discover, develop and commercialize new therapeutics itself and with strategic partners.
--------------------------------------------------------------------------------
On October 9, 2007, MultiCell executed an exclusive license and purchase agreement (the "Agreement") with Corning Incorporated ("Corning") of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell MultiCell's Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (ADME/Tox assays). Corning paid MultiCell a non-refundable license fee, purchased certain inventory and equipment related to MultiCell's Fa2N-4 cell line business, hired certain MultiCell scientific personnel, and paid for access to MultiCell's laboratories during the transfer of the Fa2N-4 cell lines to Corning. MultiCell retained and continues to support all of its existing licensees, including Pfizer, Bristol-Myers Squibb, and Eisai. MultiCell retained the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retained rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol? liver assist device, to produce therapeutic proteins using the Company's BioFactories? technology, to identify drug targets and for other applications related to the Company's internal drug development programs.
In August 2003, MultiCell signed an exclusive sales, manufacturing and distribution agreement for the use of two of its cell lines by XenoTech, an unrelated party. The agreement, which is for a term of seven years, required XenoTech to make an initial non-refundable payment of $800,000 to MultiCell in August 2003. This payment represented consideration for and a guarantee of Nosan's (XenoTech's distributor) right of first negotiation for distribution rights for the Asia Pacific Rim, should MultiCell successfully complete the development of its cell lines for the production of proteins, other cellular constituents and or drug-like molecules. Additional consideration under the August 2003 agreement included a $700,000 royalty prepayment. This prepayment was an advance against the minimum royalty payment of $800,000 for the first royalty period, which was 16 months, culminating on November 30, 2004. The subsequent 5 royalty periods will be 12 months and the last royalty period will be 8 months. XenoTech must bear all the costs for its manufacturing and sales activities and make specified minimum periodic royalty payments that total $18 million over the 7 year term of the agreement to maintain distribution exclusivity. The agreement requires XenoTech to make royalty payments to MultiCell of 17.5% of net sales for the direct sale of its cells and 34% of net sales derived from any sublicense agreement. Prior to December 1, 2004, the Company had recognized revenues under the XenoTech agreement based on the minimum royalty amount for each period because it had received a prepayment of a substantial portion of the amount due. XenoTech was required to pay a $2.1 million minimum royalty amount for the current fiscal year as a condition of its exclusivity. Since collection of the contractual amount was no longer reasonably assured and, in accordance with SEC Staff Accounting Bulletin Topic 13, commencing December 1, 2004, the Company began recognizing revenues under the XenoTech agreement based on the agreement's royalty percentage applied to XenoTech's actual sales for the period instead of the minimum royalty amount. On February 1, 2006, the Company terminated the agreement with XenoTech due to the failure of XenoTech, with due notice, to cure various breaches within the time allotted by the agreement, including the payment of minimum royalties to maintain exclusivity. As a result of this termination and the Company's recognition of the initial non-refundable payment of $800,000 over the 7-year term of the agreement, the Company recognized income for the remaining amount of deferred income of $533,334 in fiscal year ended November 30, 2006.
We have operated and will continue to operate by minimizing expenses. Our largest expenses relate to personnel and meeting the legal and reporting requirements of being a public company. By utilizing consultants whenever possible, and asking employees to manage multiple responsibilities, operating costs are kept low. Additionally, a number of employees and our Board of Directors receive Company stock in lieu of cash as all or part of their compensation to help in the effort to minimize monthly cash flow. With our strategic shift in focus on therapeutic programs and technologies, however, we expect our future cash expenditures to increase significantly as we advance our therapeutic programs into clinical trials.
We intend to add scientific and support personnel gradually. We want to add specialists for our key research areas. These strategic additions will help us expand our product offerings leading us to additional revenues and profits. Of course as revenues increase, administrative personnel will be necessary to meet the added workload. Other expenses, such as sales and customer service, will increase commensurate with increased revenues. The Company's current research and development efforts focus on development of future products and redesign of existing products. Due to the ongoing nature of this research, we are unable to ascertain with certainty the total estimated completion dates and costs associated with this research. As with any research efforts, there is uncertainty and risk associated with whether these efforts will produce results in a timely manner so as to enhance the Company's market position. Company sponsored research and development costs related to future products and redesign of present products are expensed as incurred. For the years ended November 30, 2008 and 2007, research and development costs were $317,130 and $757,866, respectively. Research and development costs include such costs as salaries, legal fees, employee benefits, compensation cost for options issued to the Scientific Advisory Board, supplies and license fees.
The Application of Critical Accounting Policies
Use of Estimates - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
--------------------------------------------------------------------------------
Research and Development - Company sponsored research and development costs related to future products and redesign of present products are expensed as incurred. Such costs are offset partly by proceeds from research grants.
Revenue Recognition - In the years covered by this report on Form 10-KSB, the Company's revenues have been generated primarily from license revenue under agreements with Corning, Pfizer, and Eisai, as well as the sale of cells or royalties on the license for the sale of cells through its sale and distribution agreement with XenoTech, LLC. Management believes such sources of revenue will be part of the Company's ongoing operations. The Company recognizes revenue from licensing and research agreements as services are performed, provided a contractual arrangement exists, the contract price is fixed or determinable and the collection of the contractual amounts is reasonably assured. In situations where the Company receives payment in advance of the performance of services, such amounts are deferred and recognized as revenue as the related services are performed. Deferred revenues associated with services expected to be performed within the 12 - month period subsequent to the balance sheet date are classified as a current liability. Deferred revenues associated with services expected to be performed at a later date are classified as non-current liabilities.
Stock-Based Compensation -We account for stock based compensation under Statement of Financial Accounting Standards 123R (SFAS 123R), which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values over the period during which an employee is required to provide service in exchange for the award (the vesting period), net of estimated forfeitures. The estimation of fair value of stock options requires management to make estimates for certain assumptions regarding risk-free interest rates, expected life of the options, expected volatility of the price of our common stock, and the expected dividend yield of our common stock.
Long-Lived Assets - Long-lived assets that do not have indefinite lives, such as property and equipment, license agreements, and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Impairment losses are recognized when events or changes in circumstances indicate that the undiscounted cash flows estimated to be generated by such assets are less than their carrying value and, accordingly, all or a portion of such carrying value may not be recoverable. Impairment losses for assets to be held and used are then measured based on the excess, if any, of the carrying amounts of the assets over their fair values. Long-lived assets to be disposed of in a manner that meets certain criteria are stated at the lower of their carrying amounts or fair values less costs to sell and are no longer depreciated.
Recent Accounting Pronouncements
In September 2006, the Financial Accounting Standards Board (FASB) issued SFAS No. 157, Fair Value Measurements (SFAS 157). SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. This statement was originally effective for financial statements issued for fiscal years beginning after November 15, 2007. In February 2008, the FASB issued FASB Staff Position (FSP FIN) No. 157-2 which extended the effective date for certain nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008. We adopted the effective portions of SFAS 157 effective December 1, 2007, which did not have a significant impact on our consolidated financial statements. We are currently evaluating the impact of the remaining portions of SFAS 157 on our financial statements and anticipate that the adoption of those portions of the statement will not have a significant impact on the reporting of our financial position and results of operations.
In March 2007, the FASB issued FASB Staff Position EITF 07-03, Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities (FSP 07-03). FSP 07-03 addresses whether nonrefundable advance payments for goods or services that will be used or rendered for research and development activities should be expensed when the advance payment is made or when the research and development activity has been performed. FSP 07-03 will be effective for fiscal years beginning after December 15, 2007, and interim periods within those fiscal years. We currently believe that the adoption of FSP 07-03 will have no material impact on our financial position or results of operations.
In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business Combinations (SFAS 141(R)), which replaces SFAS 141, Business Combinations. SFAS 141(R) retains the underlying concepts of SFAS 141 in that all business combinations are still required to be accounted for at fair value under the acquisition method of accounting, but SFAS 141(R) changed the method of applying the acquisition method in a number of significant aspects. Acquisition costs will generally be expensed as incurred; noncontrolling interests will be valued at fair value at the acquisition date; in-process research and development will be recorded at fair value as an indefinite-lived intangible asset at the acquisition date; restructuring costs associated with a business combination will generally be expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date generally will affect income tax expense. SFAS 141(R) is effective on a prospective basis for all business combinations for which the acquisition date is on or after the beginning of the first annual period subsequent to December 15, 2008, with the exception of the accounting for valuation allowances on deferred taxes and acquired tax contingencies. SFAS 141(R) amends SFAS 109 such that adjustments made to valuation allowances on deferred taxes and acquired tax contingencies associated with acquisitions that closed prior to the effective date of SFAS 141(R) would also apply the provisions of SFAS 141(R). Early adoption is not permitted. We are currently evaluating the effects, if any, that SFAS 141(R) may have on our financial statements. We do not expect that it will have any immediate effect on our financial statements, however, the revised standard will govern the accounting for any future business combinations that we may enter into.
--------------------------------------------------------------------------------
In December 2007, the FASB issued SFAS No. 160, Non-controlling Interests in Consolidated Financial Statements-an amendment of ARB No. 51 (SFAS 160). This statement is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008, with earlier adoption prohibited. This statement requires the recognition of a non-controlling interest (minority interest) as equity in the consolidated financial statements and separate from the parent's equity. The amount of net income attributable to the non-controlling interest will be included in consolidated net income on the face of the income statement. It also amends certain of ARB No. 51's consolidation procedures for consistency with the requirements of SFAS 141(R). This statement also includes expanded disclosure requirements regarding the interests of the parent and its non-controlling interest. We are currently evaluating this new statement and anticipate that the statement will not have a significant impact on the reporting of our results of operations.
In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities - an amendment of FASB Statement No. 133, (SFAS No. 161), which requires companies to provide additional disclosures about its objectives and strategies for using derivative instruments, how the derivative instruments and related hedged items are accounted for under SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, and related interpretations, and how the derivative instruments and related hedged items affect our financial statements. SFAS No. 161 also requires companies to disclose information about credit risk-related contingent features in their hedged positions. SFAS No. 161 is effective for fiscal years and interim periods beginning after November 15, 2008. We do not currently believe adoption will have a material impact on our financial position or operating results.
In May 2008, the FASB issued SFAS 162, The Hierarchy of Generally Accepted Accounting Principles. SFAS No. 162 identifies the sources of accounting principles and provides entities with a framework for selecting the principles used in preparation of financial statements that are presented in conformity with GAAP. The current GAAP hierarchy has been criticized because it is directed to the auditor rather than the entity, it is complex, and it ranks FASB Statements of Financial Accounting Concepts, which are subject to the same level of due process as FASB Statements of Financial Accounting Standards, below industry practices that are widely recognized as generally accepted but that are not subject to due process. The Board believes the GAAP hierarchy should be directed to entities because it is the entity (not its auditors) that is responsible for selecting accounting principles for financial statements that are presented in conformity with GAAP. The adoption of FASB 162 is not expected to have a material impact on our financial statements.
In May 2008, the FASB issued FASB Staff Position No. APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement (FSP APB 14-1) that changes the method of accounting for convertible debt securities that require or permit settlement in cash either in whole or in part upon conversion. FSP APB 14-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. Under FSP APB 14-1, the debt and equity components of convertible debt securities that may be settled in cash upon conversion will be bifurcated and accounted for separately in a manner that will result in recognizing interest expense on these securities at rates reflective of the entity's borrowing rates for what the entity would have incurred had it issued nonconvertible debt with otherwise similar terms. The equity component of such convertible debt securities will be included in the paid-in-capital section of stockholders' equity on the consolidated balance sheet and, accordingly, the initial carrying values of these debt securities will be reduced. Net loss for financial reporting purposes will be increased by recognizing the accretion of the reduced carrying value of the convertible debt securities to their face amounts as additional non-cash interest expense. Management is currently evaluating the impact of FSP APB 14-1 on our financial statements, but has not yet determined the effect on the reporting of our consolidated financial position and results of operations.
In June 2008, the FASB ratified EITF Issue No. 07-5, Determining Whether an Instrument (or an Embedded Feature) Is Indexed to an Entity's Own Stock (EITF 07-5). EITF 07-5 provides that an entity should use a two step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument's contingent exercise and settlement provisions. It also clarifies on the impact of foreign currency denominated strike prices and market-based employee stock option valuation instruments on the evaluation. EITF 07-5 is effective for fiscal years beginning after December 15, 2008. Management is currently evaluating the impact of EITF 07-5 on our financial statements, if any, that will occur upon the adoption of EITF 07-5.
--------------------------------------------------------------------------------
Results of Operations
The following discussion is included to describe our consolidated financial position and results of operations. The consolidated financial statements and notes thereto contain detailed information that should be referred to in conjunction with this discussion.
Year Ended November 30, 2008 compared to Year Ended November 30, 2007
Revenue. Total revenue for the year ended November 30, 2008 was $209,835, as compared to revenue of $251,797 for the same period in the prior fiscal year, a decrease of $41,962. For the year ended November 30, 2008, revenue consisted of license revenue totaling $190,521 under agreements with Corning, Pfizer, Eisai, and Xenotech, plus revenue of $19,314 from sales of cells and related media. For the year ended November 30, 2007, revenue consisted of license revenue totaling $131,664 under agreements with Pfizer, Eisai, Xenotech, and BMS, plus revenue of $120,133 from sales of cells and related media.
Operating Expenses. Total operating expenses for the year ended November 30, 2008 were $2,300,818, as compared to operating expenses of $3,389,894 for the year ended November 30, 2007, representing a decrease of $1,089,076 as compared to the prior fiscal year. This decrease principally represents the net effect of the following changes between 2008 and 2007: 1) the reduction in 2008 of the costs for consulting fees, legal fees, accounting and auditing fees, and other professional fees by approximately $1,150,000; 2) the reduction in 2008 of salaries and wages, including related benefits and payroll taxes, by approximately $480,000; 3) the reduction in 2008 of the costs of occupancy in the approximate amount of $190,000; 4) the write-off in 2007 of certain license fees in the amount of $300,000 that had been capitalized in 2006 (none in 2008); and 5) the write-down of intangible assets due to impairment in value in 2008 in the approximate amount of $1,060,000. The Company has reviewed its patent portfolio strategy related to its Toll-like receptor 3 (TLR3) technology acquired in September 2005 when MultiCell acquired the assets of Astral, Inc. This intellectual property is the subject of three patent applications, and is related to the Company's lead drug candidate MCT-465. The Company may decide to cease further prosecution of the subject patent applications and terminate its development work related to MCT-465. Accordingly, the Company has written down the value of the patent applications directly related to MCT-465 presently carried on its balance sheet at November 30, 2008.
Other income/(expense).The total of other expense, net of other income, decreased from $34,541 for the year ended November 30, 2007 to $3,953 for the year ended November 30, 2008, representing a decrease of $30,588. The principal cause of the decrease is the reduction of interest expense and related amortization of discount for the 7.75% convertible debentures, which were issued early in 2007, then paid off or converted into common stock by February 2008.
Net Loss. Net loss for the year ended November 30, 2008 was $2,094,936, as compared to a net loss of $3,172,638 for the year ended November 30, 2007, representing a decrease in the net loss of $1,077,702 (34%). The primary reasons for the decrease are the reductions in operating expenses as described above, net of the effects of the write-down of intangible assets due to impairment in value.
Preferred stock dividends. In connection with the issuance of the Series B preferred stock and warrants, commencing on the date of issuance of the Series B preferred stock until the date a registration statement registering the common shares underlying the preferred stock and warrants issued is declared effective by the SEC, the Company will pay on each outstanding share of Series B preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying (A) $100 per share by the higher of the Wall Street Journal Prime Rate plus one percent (1%), or nine percent (9%). In no event will the dividend rate be greater than 12% per annum. The dividend shall be payable monthly in arrears in cash on the last day of each month based on the number of shares of Series B preferred stock outstanding as of the first (1st) day of such month. In the event the Company does not pay the Series B preferred dividends when due, the conversion price of the Series B preferred shares will be reduced to eighty-five percent (85%) of the otherwise applicable conversion price. For the years ended November 30, 2008 and 2007, the Company paid and/or accrued preferred dividends in the amount of $149,203 and $151,548, respectively.
Liquidity and Capital Resources
Since our inception, we have financed our operations primarily through the issuance of debt or equity instruments. The following is a summary of our key liquidity measures at November 30, 2008 and November 30, 2007:
--------------------------------------------------------------------------------
November 30, 2008 November 30, 2007
Cash and cash equivalents $ 6,022 $ 411,691
Current assets $ 38,876 $ 502,704
Current liabilities (1,768,689 ) (1,724,869 )
Working capital deficiency $ (1,729,813 ) $ (1,222,165 )
The Company will have to raise additional capital in order to initiate Phase IIb clinical trials for MCT-125, the Company's therapeutic product for the treatment of fatigue in multiple sclerosis patients. Management is evaluating several sources of financing for its clinical trial program. Additionally, with our strategic shift in focus to therapeutic programs and technologies, we expect our future cash requirements to increase significantly as we advance our therapeutic programs into clinical trials. Until we are successful in raising additional funds, we may have to prioritize our therapeutic programs and delays may be necessary in some of our development programs.
During the past fiscal year (and into the current fiscal year), the Company has operated on working capital provided by LJCI in connection with its exercise of warrants issued to it by the Company (which LJCI must exercise whenever it wants to convert amounts owning under the convertible debenture it holds), all as discussed in more detail below. The warrants are exercisable at $1.09 per share. As of March 9, 2009 there were 9,683,500 shares remaining on the stock purchase warrant. Should LJCI continue to exercise all of its remaining warrants approximately $10.6 million of cash would be provided to the Company. However, the Debenture Purchase Agreement (discussed below) limits LJCI's stock ownership in the Company to 9.99% of the outstanding shares of the Company and therefore, based on the number of shares outstanding as of March 9, 2009. The Company expects that LJCI will continue to exercise the warrants and convert the debenture over the next year, but cannot assure that LJCI will do so. We are investigating the possible sale or license of certain assets that we did not already license to Corning in October 2007. We are presently pursuing discussions with companies operating in the stem cell research market and the general life science research market.
On May 3, 2006, MultiCell entered into a common stock purchase agreement with Fusion Capital, which was amended and restated on October 5, 2006, and ultimately terminated on July 18, 2007. Under the agreement, Fusion Capital was obligated, under certain conditions, to purchase shares from the Company up to an aggregate amount of $8 million from time to time over a 25-month period. MultiCell authorized 8,000,000 shares of its common stock for sale to Fusion Capital under the agreement. For the year ended November 30, 2007 the Company received $450,000 from Fusion Capital of which 25% of the gross proceeds were payable to Series B preferred shareholders. During the year ended November 30, 2007, the Company redeemed 615 shares of Series B preferred stock by paying $61,500.
As consideration for entering into the original transaction on May 3, 2006, MultiCell issued to Fusion Capital 1,572,327 shares of its common stock and warrants to purchase an additional 1,572,327 shares of its common stock at a price of $0.01 per share. Upon execution of the amended and restated purchase agreement on October 5, 2006, Fusion Capital retained the original 1,572,327 shares of common stock and returned the warrant to the Company.
-----------------------------------------
Cheers All,
TheGoodlifeGeo
But it does not matter here because Greg has done Nothing Wrong! All these Idiots who are blasting this board with Spam postings of doom and gloom are either just here to cause trouble or want your shares cheaper.
The best way to counteract them is Ignore Them!
I have also been told there is a New Breed of bashers here growing in numbers. Just here to cause trouble and nothing else... I had one long time friend out here say they think it is Kids just bashing for Kicks and to get a reaction. Be Smart.
They said it would take 1-4 weeks to complete the name change. When Greg has something to tell us he will. When the site is ready it will be up. Take a chill pill and relax. Nothing has changed with this company and if anyone thinks Greg will take a chance with the SEC and go back to jail, you are Totally Nuts.
This is a Real company with Real revenues and we Will reap those rewards.
Greg wants to make money and has already told us he wants us all to make money. Let him do this for us in his way and he will.
All this is IMHO...
Cheers and GTLA,
TheGoodlifeGeo
Wow... I must not be saying the right things because I have never had a 'stalker' (yet) LOL...
Funny in a sad kind of way...
Anyway, I met someone elsewhere on Ihub and pointed her to this board. She saw your post about MESA and bought some...
Good Call! Up almost 15% today alone. Nice...
Anyway, have a great weekend all.
Cheers,
TheGoodlifeGeo
Aloha Tiki and same to you!
I have some new plays that might be fun to watch... I am about to head to sleepy land though, so I will not see it...
Cheers All,
TheGoodlifeGeo
I bought 6000 shares of HGSI last night just before the close...
BTW, I did another of those CITI things... Bought when it hit 1.02 and today it is sitting at 1.67
This is starting to become my biggest gainer/profitmaker...
I am starting to think it will go back up to the $3 range where it was a few weeks back.
I think I let it ride to see...
Cheers All,
TheGoodlifeGeo
Thanks... A lot of good stuff here lately... I have been actively emailing the company for days now and even though they cannot and will not divulge anything of any nature that would cause the SEC to raise their eyebrows, I am heartened by the responses that I have received. I even got a Thank You for some of the thoughts I shared with the person I was writing to.
I have decided I officially like this company... And I do not like many...
I think I will stick around for a while and see what happens next...
Cheers and GTLA,
TheGoodlifeGeo
Well Friend, at 51 years old, I do not pretend to know everything, but I know that part of my own DD includes things just like what I reported.
If you enjoy reading my posts great. If not, you are free not to read them... Is not Democracy Wonderful!?
I Absolutely agree that the Stock market has been and always will be the biggest Racket the world will ever know...And that is JMHO
Cheer Mate,
TheGoodlifeGeo